§ 17-184.2 Availability of rapid testing for sexually transmitted infections.
AC § 17-184.2
a. Definitions. For the purposes of this section, the term “rapid testing” means testing for chlamydia, gonorrhea, or HIV that produces results in the same day. b. Availability. The department shall make rapid testing available at sites in at least 4 boroughs. Three such sites shall be operational by February 15, 2026, and the fourth such site shall be operational by February 15, 2027. In determining the location of rapid testing sites, the department shall consider community and geographic factors including rates of sexually transmitted infections, availability of other testing services, social determinants of health, including, but not limited to, race, ethnicity, sexual orientation, and gender identity, and other factors the department deems relevant. Within 30 days of determining each such location, the commissioner shall notify in writing the mayor and speaker of the council of the considerations that went into such determination. c. Outreach. Upon the establishment of any rapid testing site required pursuant to subdivision b of this section, the department shall consult or partner with relevant community-based organizations and shall conduct an education campaign in English and the designated citywide languages as defined in section 23-1101 to inform communities of the locations and availability of rapid testing services. In determining relevant community-based organizations to consult or partner with, the department shall consider community and geographic factors including rates of sexually transmitted infections, availability of other testing services, social determinants of health, including, but not limited to, race, ethnicity, sexual orientation, and gender identity, and other factors the department deems relevant. d. Disclaimer. Nothing in this section shall require the department to provide rapid testing services to a patient for whom the department or the medical provider administering such services does not find such rapid testing to be clinically appropriate. (L.L. 2024/084, 8/17/2024, eff. 8/17/2024) Editor's note: For related unconsolidated provisions, see Appendix A at L.L. 2024/084.
